USX:LABP - Landos Biopharma Inc Landos Biopharma Inc
Sector: Health Care, Industry: Biotechnology
Next Earnings: 10 May 2024
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 21.36    -0.2 (-0.93%)

27 Mar 2024


Loading...
Loading...
Loading...

General

CEO: Mr. Gregory Oakes

IPO: 2021-02-04

Headquarters: US

Employees: 22

Homepage

Description

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages. The company's pipeline includes NX-13, LABP-66, LAPB-73, LABP-69. The company's current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist.

Your Holdings
Dashboard
Portfolio
Options

Tools
Screener
Watchlist
Alerts
Notes
Community
Forum
Blog
YouTube
Shared Portfolios
Shared Screeners

Collab with Brokerages
Moomoo x StocksCafe
Tiger x StocksCafe

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Bombay
National (India)
Indexes
Singapore Savings Bonds
Singapore T-Bills
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
YouTube
Server T1

About · FAQs · StocksCafe © 2024 · Privacy · Terms